Stockreport

LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D [Yahoo! Finance]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF once-weekly weight-loss drug, retatrutide, in adults with type II diabetes (T2D) This study, called TRANSCEND-T2D-1, evaluated three doses (4 mg, 9 mg and 12 mg) of th [Read more]